Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial

• Váldodahkkit: Lina Cordero De Los Santos (Dahkki), Jesús Feris-Iglesias (Dahkki), Naveena Aloysia D'Cor (Dahkki), Venkata Jayanth Midde (Dahkki), Badri Narayan Patnaik (Dahkki), Yaël Thollot (Dahkki), Anvar Rasuli (Dahkki), Eric Desauziers (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2018-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

The Dominican Republic, historically non-endemic for cholera, is experiencing an ongoing cholera epidemic. We assessed the safety and immunogenicity of two doses of the killed bivalent (O1 and O139) whole-cell oral cholera vaccine (OCV) on day (D)0 and D14 in healthy participants aged ≥1 year. Immed...